Type II Diabetes Mellitus Patient Preference Study - Trial PHRR210913-003895
Access comprehensive clinical trial information for PHRR210913-003895 through Pure Global AI's free database. This Phase 4 trial is sponsored by AstraZeneca Pharmaceuticals (Philippines) Inc. and is currently Ongoing. The study focuses on Type 2 Diabetes Mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR210913-003895
Phase 4
Ongoing
Trial Details
Philippine Health Research Registry • PHRR210913-003895
Type II Diabetes Mellitus Patient Preference Study
Cross-sectional evaluation on the preference of oral agent for the treatment of diabetes (sodium-glucose cotransporter 2 inhibitor, SGLT2I) vs. dipeptidyl peptidase-4 inhibitor, DPP4I) in patients with type 2 diabetes mellitus (T2DM)
Study Focus
Observational
Sponsor & Location
AstraZeneca Pharmaceuticals (Philippines) Inc.
Philippines
Timeline & Enrollment
Phase 4
Oct 01, 2021
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Philippine Health Research Registry
PHRR210913-003895
Non-Device Trial